![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1562, 2006-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tocilizumab adds to benefit with methotrexate in refractory RA
Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tocilizumab dominates adalimumab for severe RA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 669, 2013-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tocilizumab + methotrexate effect on liver enzymes `manageable'
Reactions Weekly, Vol. 1, Iss. 1278, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Adalimumab adds to methotrexate efficacy in RA
Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Ocrelizumab + methotrexate well tolerated in RA
Inpharma, Vol. 1, Iss. 1615, 2007-01 ,pp. :